We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Promega Partners with ATCC to Offer New Cell Systems for Biologics Drug Discovery
News

Promega Partners with ATCC to Offer New Cell Systems for Biologics Drug Discovery

Promega Partners with ATCC to Offer New Cell Systems for Biologics Drug Discovery
News

Promega Partners with ATCC to Offer New Cell Systems for Biologics Drug Discovery

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Promega Partners with ATCC to Offer New Cell Systems for Biologics Drug Discovery"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Promega Corporation and ATCC (historically known as the American Type Culture Collection) have formed a partnership for the cell banking and bioproduction of cells to create a new line of bioluminescence-based drug discovery assays for biologics.

In the partnership, ATCC will produce and authenticate cell banks and production lots of engineered and stock cell lines, which will be used as cellular reagents to create a new line of Promega cell assay systems for biologics. The initial cell assay system will facilitate biologics drug discovery.

Promega will launch an ADCC reporter bioassay in 2011 as the first product offering from this partnership. The ADCC (Antibody Dependent Cell-mediated Cytotoxicity) reporter bioassay will meet a particularly critical need for nearly all antibody-based biologics drug discovery programs worldwide.

These and other custom cell system assays will provide reduced variability to bioassays for biologics. The ADCC and other bioassay systems are currently in alpha and beta testing programs for qualification by leading manufacturers of biologics drugs.

ATCC is the recognized leader in biological materials management and processes for cell provisioning. "We are extremely pleased to work with Promega in bringing their assay innovations to drug discovery researchers", said Dr. Sherry Challberg, Sr. Director of Corporate Development for ATCC.

ATCC's President, Dr. Brian Pollok added, "We are excited to begin a venture of working with technology-based companies like Promega in the area of cellular assay product development."

Promega's Vice President of Life Sciences Products and Services, Thomas Livelli commented, "We believe this new offering will be extremely helpful to scientists and provide high value cell-based systems for discovery and development."

Advertisement